The presentation, scheduled for 11:30 a.m. UK time, brings together clinicians and healthcare leaders to examine emerging cancer care strategies. Bosch plans to detail the clinical trial results of the company's DCVax platform, specifically addressing how personalized treatments aim to improve patient outcomes while avoiding the toxicities common in traditional chemotherapy. The discussion will also cover potential combination therapies and the broader shift toward dendritic cell-based immunotherapy.

Northwest Biotherapeutics currently has its DCVax-L treatment for glioblastoma—an aggressive form of brain cancer—under regulatory review in the UK following a 331-patient Phase III trial. Results from this study were previously published in JAMA Oncology. Beyond glioblastoma, the company is preparing for Phase II trials for DCVax-Direct, a treatment candidate for inoperable solid tumors that previously completed a 40-patient Phase I study. The company intends to release the conference slide deck on its website following the event.